Literature DB >> 2766243

Cytogenetic studies of 103 patients with acute myelogenous leukemia in relapse.

O M Garson1, A Hagemeijer, M Sakurai, B R Reeves, G J Swansbury, G J Williams, G Alimena, D C Arthur, R Berger, A de la Chapelle.   

Abstract

In order to investigate the cytogenetic patterns in relapsed acute myelogenous leukemia (AML), a clinical and cytogenetic follow-up of patients newly diagnosed for the Fourth International Workshop on Chromosomes in Leukemia (4IWCL) was evaluated at the 6IWCL. Information was received on 103 patients in relapse who were then classified into seven groups according to the diagnostic karyotype. These groups were: normal, t(8;21), t(15;17), +8, a single specific abnormality either numerical or structural other than those already listed, a single nonrandom or miscellaneous abnormality again either numerical or structural, and complex abnormalities. The patient's age, diagnostic FAB type, the number of relapses, the total survival time, and the karyotype in relapse were considered in each of these cytogenetic groups. The remission and survival rates were comparable in all groups except the +8 group, where patients relapsed earlier and had a shorter survival time. Multiple relapses occurred most frequently in the t(8;21) group, whereas none of the patients with t(15;17) relapsed more than once, although the total survival time was similar to the two groups. Thirty-nine percent of the patients relapsed with the same karyotype as at diagnosis. A more complex karyotype showing evolution was found in 53%, and 8% showed either a less-complicated karyotype or appeared to have reverted to normal. Numerical abnormalities in relapse frequently involved trisomy of chromosomes 8 and/or 21. There was a nonrandom development of 9q- with relapse in patients with t(8;21). A pericentric inversion of chromosome 4, and abnormality infrequently reported at diagnosis, was found in relapse in association with t(15;17), t(8;21), and +8 karyotypes. Changes considered to be typically secondary in nature involving 5q, 7q, and 12p were seen in only seven cases. Twenty-one patients who had an apparently normal karyotype at diagnosis remained normal in relapse, indicating that absence of clonal chromosome abnormality is a real observation in AML rather than a failure of detection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2766243     DOI: 10.1016/0165-4608(89)90024-1

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  11 in total

1.  Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia.

Authors:  Bruno C Medeiros; Megan Othus; Min Fang; Frederick R Appelbaum; Harry P Erba
Journal:  Haematologica       Date:  2014-12-19       Impact factor: 9.941

2.  Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia.

Authors:  Brian Parkin; Peter Ouillette; Yifeng Li; Jennifer Keller; Cindy Lam; Diane Roulston; Cheng Li; Kerby Shedden; Sami N Malek
Journal:  Blood       Date:  2012-11-21       Impact factor: 22.113

3.  High frequency of rare structural chromosome abnormalities at relapse of cytogenetically normal acute myeloid leukemia with FLT3 internal tandem duplication.

Authors:  Theodore S Gourdin; Ying Zou; Yi Ning; Ashkan Emadi; Vu H Duong; Michael L Tidwell; Ching Chen; Feyruz V Rassool; Maria R Baer
Journal:  Cancer Genet       Date:  2014-09-16

Review 4.  Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia.

Authors:  T Bochtler; S Fröhling; A Krämer
Journal:  Leukemia       Date:  2015-02-12       Impact factor: 11.528

Review 5.  Cytogenetics in acute myeloid leukemia.

Authors:  Claudia Schoch; Torsten Haferlach
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

6.  Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.

Authors:  Li Ding; Timothy J Ley; David E Larson; Christopher A Miller; Daniel C Koboldt; John S Welch; Julie K Ritchey; Margaret A Young; Tamara Lamprecht; Michael D McLellan; Joshua F McMichael; John W Wallis; Charles Lu; Dong Shen; Christopher C Harris; David J Dooling; Robert S Fulton; Lucinda L Fulton; Ken Chen; Heather Schmidt; Joelle Kalicki-Veizer; Vincent J Magrini; Lisa Cook; Sean D McGrath; Tammi L Vickery; Michael C Wendl; Sharon Heath; Mark A Watson; Daniel C Link; Michael H Tomasson; William D Shannon; Jacqueline E Payton; Shashikant Kulkarni; Peter Westervelt; Matthew J Walter; Timothy A Graubert; Elaine R Mardis; Richard K Wilson; John F DiPersio
Journal:  Nature       Date:  2012-01-11       Impact factor: 49.962

7.  Evaluation of prognostic factors in patients with relapsed AML: Clonal evolution versus residual disease.

Authors:  Hyojeong Kim; Young Mi Seol; Moo-Kon Song; Young Jin Choi; Ho-Jin Shin; Sang Hyuk Park; Eun Yup Lee; Joo-Seop Chung
Journal:  Blood Res       Date:  2016-09-23

Review 8.  Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia.

Authors:  Hubert Hackl; Ksenia Astanina; Rotraud Wieser
Journal:  J Hematol Oncol       Date:  2017-02-20       Impact factor: 17.388

9.  HEMOPHAGOCYTOSIS BY BLASTS IN A CHILD WITH ACUTE MONOCYTIC LEUKEMIA AFTER CHEMOTHERAPY.

Authors:  Mariela Granero Farias; Priscila Aparecida Correa Freitas; Fabiane Spagnol; Meriene Viquetti de Souza; Ana Paula Alegretti; Mariluce Riegel; Adriano Nori Rodrigues Taniguchi; Liane Esteves Daudt
Journal:  Rev Paul Pediatr       Date:  2020-07-03

10.  The Association between PARP1 and LIG3 Expression Levels and Chromosomal Translocations in Acute Myeloid Leukemia Patients.

Authors:  Hossein Pashaiefar; Marjan Yaghmaie; Javad Tavakkoly-Bazzaz; Seyed Hamidollah Ghaffari; Kamran Alimoghaddam; Pantea Izadi; Ardeshir Ghavamzadeh
Journal:  Cell J       Date:  2018-03-18       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.